KURA ONCOLOGY, INC. Debt Securities, Available-for-sale, Unrealized Loss
KURA ONCOLOGY, INC. (KURA) reported Debt Securities, Available-for-sale, Unrealized Loss of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2021-02-24.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2021-02-24
- KURA ONCOLOGY, INC. debt securities, available-for-sale, unrealized loss for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- KURA ONCOLOGY, INC. debt securities, available-for-sale, unrealized loss for fiscal 2018 was $93.50M, a 203.57% increase from fiscal 2017.
- KURA ONCOLOGY, INC. debt securities, available-for-sale, unrealized loss for fiscal 2017 was $30.80M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|
| 2019-12-31 | $0.00 10-K · filed 2021-02-24 |
| 2018-12-31 | $93.50M 10-K · filed 2020-02-25 |
| 2017-12-31 | $30.80M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |